Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of T4090 in Glaucoma or Ocular Hypertension
NCT05389267Phase 2Active, not recruiting
- Sponsor
- Laboratoires Théa
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Ocular and systemic adverse events at 22 days. Started Jul 2022; status: active, not recruiting.
02
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT05389267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389267.